嵌合抗原受体T细胞疗法专利态势分析

嵌合抗原受体T细胞疗法是最有可能战胜癌症的肿瘤免疫疗法，是生命科学领域极具发展前景的前沿产业，对知识产权的保护至关重要。本文对嵌合抗原受体T细胞疗法的国际和国内专利态势进行分析，包括对专利申请趋势、专利产出国、专利应用国、主要申请人、技术聚类主题等进行分析，从而比较我国与国际的差距与不足，有助于我国嵌合抗原受体疗法行业更好地运用专利手段保护自身知识产权，促进企业创新发展。本文研究发现，相比于美国，我国科研院所在嵌合抗原受体T细胞疗法领域的专利产出不高，反应了我国在该技术基础研究投入方面的不足，我国对全球范围内的专利布局也缺乏重视。建议我国应加大对嵌合抗原受体T细胞疗法的基础研发投入，开发和掌握关键技术；注重国际专利布局，增强国际市场竞争力；强化科研院所和企业之间的联动合作，以鼓励和促进专利技术的转化。

Research on the Patent Trend of Chimeric Antigen Receptor T Cell Therapy

Chimeric antigen receptor T cell therapy, the most likely tumor immunotherapy to overcome cancer, is a promising frontier industry in the field of life sciences, and it is vital to protect the intellectual property rights. This article analyzes the international and domestic patent situation of chimeric antigen receptor T cell therapy, including the analysis of patent application trends, patent producing countries, patent application countries, main applicants, and technology clustering topics, to compare the gaps and deficiencies between China and the world. This would be helpful for tumor immunotherapy industry to better use patented means to protect its own intellectual property rights and promote enterprise innovation and development. This research finds that, compared with the United States, our investment in basic research in CAR-T technology is seriously insufficient, and there is a lack of attention to the global patent layout. It is suggested that we should increase investment in basic R&D in the field of CAR-T technology, in order to develop and master key technologies; focus on the layout of foreign patents to enhance international market competitiveness; strengthen the linkage and cooperation between scientific research institutes and enterprises to promote the transformation of patent technology.